United States / English

EMD Millipore is now MilliporeSigma

EB Programs: Our Grant Programs

Unlock your molecule's potential.

We understand the challenges emerging biotech companies face in the quest to push the next generation of drugs to market. This is why we have developed our Advance Biotech Grant programs which occur on regular basis in different regions of the world. These programs allow grant recipients receive free products and services.

2021 North America

Apply to our Advance Biotech Grant Program Today!

Your promising molecule requires resources and support to realize its potential. Our Advance Biotech Grant Program is open to US and Canadian biotech companies, to help you accelerate to clinic faster. Apply before September 20, 2021 for a chance to win bioprocessing**/Actives and Formulation products and consultation.

  • $160,000 in Bioprocessing Technologies
  • $40,000 in Bioprocess Technologies consultation services
  • $40,000 in the Actives and Formulation (A&F)
  • $15,000 in a full subscription to the Emprove® Suite for one-year period plus an online training on the Emprove® program and regulations

Apply Now

Learn More

Rules & Regulations

2021 Europe

Congratulations VectorY- Winner

The Winner will receive 255,000€ to be used for the purchase the following:

  • 160,000€ in bioprocess technologies
  • 40,000€ in bioprocess consulting services
  • 40,000€ in Actives and Formulations catalogue portfolio for biomolecule formulation
  • 15,000€ in a full subscription to Emprove® Suite for one-year period

Congratulations to semi-finalists:

2020 US & Canada

Congratulations to the team at Combined Therapeutics, Inc for being awarded the 2020 North America Advance Biotech Grant grand prize of $250,000 in products, services and consultation. With a large number of applicants this year, 10 semi-finalist companies were selected to present directly to the panel of judges, from there- 3 finalist companies were selected to move forward. Two companies, Tenaya Therapeutics and Respana Therapeutics, will receive $10,000 in products and services. The Advance Biotech Grant Program is a global program that helps biotech startups understand the challenges in the quest to push the next generation of drugs to market.

2020 Europe

Congratulations Ali Salanti and VAR2 Pharmaceuticals team!

VAR2 Pharmaceuticals is a biotechnology company engaged in the design and development of proprietary therapeutic proteins targeting cancer-specific carbohydrate structures for multiple cancer indications. They have a portfolio of proteins with unique affinity and specificity for these cancer-associated carbohydrates for the development of treatments for cancers where there is no effective therapy, such as sarcoma, triple negative breast cancers and prostate cancer.

Additional congratulations to our semifinalists!

Our Advance Biotech Grant Program, 9th edition, is closed.

2019 Taiwan

Our Advance Biotech Grant Program in Taiwan

We have hosted our 6th edition, for Taiwanese biotech companies, to help accelerate molecules to the clinic faster.

First Prize
  • Mycenax Biotech Inc.
Second Prize
  • PharmaEssentia Corporation
BioReliance® End to End Special Prize
  • AbGenomics International, Inc.
BioReliance® End to End Excellence Prize
  • AnTaimmu BioMed Co., Ltd.

2019 China

Our Advance Biotech Grant Program in China

Apply now for a chance to win free process solution products and services; and/or process development support.

First Prize
  • Sound Biopharmaceuticals Co., Ltd.
Second Prize
  • Elpiscience Biopharma, Ltd.
Third Prize
  • HanX Biopharmaceuticals, INC.
BioReliance® End-to-End Excellence Prize
  • Hangzhou Sumgen Biotech Co., Ltd.

2018 - 2019 USA and Canada

Our 2019 Advance Biotech Grant Program for North America

We have hosted our 2019 Advance Biotech Grant Program for North American biotech companies, to help you accelerate to clinic faster.

The three grant recipients are:

  • RAFT Pharmaceuticals (San Diego, California), for its approach to treat chronic pain using a biologic to selectively inhibit neuroinflammation without affecting normal motor or sensory function.

  • Rubicon Biotechnology (Anaheim, California), for developing a therapeutic protein, Fv-Hsp72, designed to protect and salvage cells damaged from an acute event, such as traumatic brain injury.

  • TechnoVax Inc (Elmsford, New York), for developing a virus-like particle platform that facilitates the development and production of a range of vaccines targeting the prevention of respiratory diseases, hemorrhagic fevers, immunodeficiency and cancers.
In support of the growing biotech ecosystem, grant recipients receive between $40,000 and $100,000 in MilliporeSigma products and process development support.

Read the Grant winner announcement

2018 - Europe

Our 2018 Advance Biotech Grant Program for Europe

We have hosted our 2018 Advance Biotech Grant Program, the 5th edition, for European* biotech companies, to help you accelerate to clinic faster.


  • GenoScience Pharma (France), to explore new agents such as GNS561 — a never-before-used mechanism-of-action in commercialized cancer treatments / anti-cancer drugs in the pipeline.

  • GlioCure (France), for developing an anti-tumor and neuroprotective peptide, GC01, to treat the most frequent and aggressive type of brain tumor, glioblastoma.

  • ResoTher Pharma (Denmark), to develop new medicines for cardiovascular and inflammatory disorders.
Each grant recipient has received between €50,000 and €100,000 in MilliporeSigma products and services to help solve their challenges.

Read the Grant winner announcement

[*Netherlands, Belgium, Switzerland, United Kingdom, Ireland, France, Germany, Denmark, Finland, Norway, Austria, Spain, Sweden]

2016 - Europe


  • GeneQuine Biotherapeutics (first prize), for developing novel therapies for osteoarthritis, a degenerative joint disease with high unmet medical need
  • TILT Biotherapeutics (second prize), for enabling tumor T-cell therapy with oncolytic viruses.
  • Reneuron (third prize), for developing novel stem cell therapies targeting areas of significant unmet or poorly met medical need
  • Magnus Life Science (fourth prize), for funding, building and managing companies to translate innovative, curiosity driven science into therapeutics and devices that bring significant benefits to patients

Recipients received between €25,000 and €100,000 in technologies and services to accelerate therapeutics to market. View Press Release.

2015 - Asia


  • Beijing Biokey, for developing a monoclonal antibody for the treatment of fibriotic disease
  • Guangdong Jia Genetic Medicine Engineering Research Center, for developing novel therapies to treat cancer and autoimmune diseases
  • Hangzhou DAC Biotech, for developing antibody drug conjugates to treat cancer
  • Akeso Biopharma, for developing a pipeline of antibodies targeting cancer, cariovascular and immune diseases
  • Shanghai Mattel Biotechnology, for developing an innovative long acting fusion FVIII to treat hemophilia

Each grant recipient received 280,000 CNY in technologies and services.

2014 - USA


  • NGM Biopharmaceuticals, for developing biologics for the treatment of cardiometabolic conditions, bile acid-related disease, and potentially other diseases resulting from manifestations of cardiometabolic abnormalities and metabolic related cancers

NGM was awarded $89K in products and services. View Announcement.

Best practices for biotechnology companies from industry experts. Click on a topic to learn more.

If you want to be contacted regarding our next Emerging Biotech Grant Program, please leave your details and we will contact you.

Biotech Resource Hub: Stay Current

Advance Biotech Grant Program – Accelerating Therapeutic Development in Life Science

The Life Science business of MilliporeSigma is expanding its commitment to the global biotech community with its Advance Biotech Grant Program. Through the newly expanded grant program, every six months, three recipients around the globe will be awarded a total of €200,000 in free services and products to address their process development challenges. In total, six companies will benefit from the Advance Biotech Grant Program each year. Press Release

Find out more about our programs:

Bringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.

More details about EB Programs>

WEBINAR: Accelerated ADC Development with Integrated Supply Chain Solutions

Learn more about the advantages to work with one source on your mAb, linker/ payload supplies and conjugation services.

Watch Now >

WEBINAR: RNA Based Therapeutics and Vaccines: Bioprocessing Technology Trends

Review the current dynamics in the RNA therapeutics/vaccines market with a focus on process development and manufacturing strategies.

Watch this Webinar >

WEBINAR: Managing Process Scale-up and Tech Transfer

Learn more on points to consider for successful tech transfers with a focus on cGMP training requirements.

Watch this Webinar >

Webinars On-Demand >

WHITE PAPER: 2017 Life Science Executive Summit

Establishing an open dialog within the biotech community....

Read more and download >

The Changing Biopharma Risk Equation

A report from the The Economist Intelligence Unit sponsored by MilliporeSigma.
This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.

Read the study >

Contact Us

Research. Development. Production.

We are a leading supplier to the global Life Science industry: solutions and services for research, development and production of biotechnology and pharmaceutical drug therapies.

© 2017 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
EMD Millipore is a part of Merck KGaA, Darmstadt, Germany.